Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

APHA awarded $100,000 to develop brucellosis vaccine
Wholesale vaccination of livestock can be a cost-effective way of controlling brucellosis.
Vaccine to deliver lasting benefits to human and animal health

The Animal and Plant Health Agency (APHA) has been awarded $100,000 in the AgResults’ Brucellosis Vaccine Prize competition. The money will be used to develop a vaccine that is effective for use against small ruminants across the developing world.

The APHA received the funding for Phase 1 of the vaccine development and was awarded based on the agency's scientific soundness, suitable research and appropriate manufacturing capabilities.

Dr John McGiven, who is leading the project, said: “We feel the AgResults competition elevates recognition of the significance of this insidious and debilitating disease. For many years we have been focusing on improved methods for the serodiagnosis of brucellosis and this research revealed to us a route towards a new type of vaccine against brucellosis.

“This competition gave us additional incentive to pull these innovative concepts together in the belief that we can make a big difference to brucellosis control.”

Brucellosis is a devastating disease that leads to infertility, abortions and decreased milk production. It affects many animals, including small ruminants and is endemic in a number of developing countries.

Wholesale vaccination of livestock can be a cost-effective way of controlling the disease and reducing its impact on human and animal health. However, existing vaccines are unsafe for use in pregnant animals, have variable efficacy, and can harm humans.

The Brucellosis Vaccine Prize Competition, managed by AgResults, has three phases and may run for 10 years. $30 million is available to entrants, with three milestone payments at different stages.

Dr McGiven’s team is now working on Phase 2 of the vaccine development, by developing a proof of concept vaccine that meets efficacy and safety requirements. It is hoped the vaccine will deliver lasting benefits to human and animal health.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.